📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-04 12:15
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Rs 29.98 Cr Acquisition & 252% PAT Growth in Q1 FY27 for Resonance Specialties
Resonance Specialties reported a robust Q1 FY27 with revenue growing 53% YoY to Rs 32.58 Cr and PAT surging 252% to Rs 5.74 Cr, driven by a 118% jump in export revenue. The company also announced the acquisition of a WHO-Geneva approved manufacturing unit in Mandideep from a promoter group company for Rs 29.98 Cr. This unit previously manufactured intermediates for the company on a job-work basis; internalizing it is expected to enhance operational control and eliminate outsourcing costs. The acquisition value is significant, representing approximately 40% of the company's net worth.
Confidence: HIGH
What changedResonance is moving from a job-work model to owning a key manufacturing facility previously held by a promoter group entity, alongside reporting a major earnings beat.
Why it mattersThe acquisition secures an uninterrupted production facility for key intermediates and APIs that the company previously lacked the technology to manufacture in-house, while the Q1 results show strong export momentum.
Acquisition Value: Rs 29.98 CrAcquisition vs Net Worth: ~40.5%Q1 PAT Growth (YoY): 252.3%Q1 Revenue Growth (YoY): 53.1%Export Revenue (Q1): Rs 23.26 Cr
📅 Short termThe stock is likely to react positively to the substantial earnings growth and the strategic backward integration through the acquisition.
📈 Long termOwning the WHO-approved facility provides structural margin benefits and better control over the supply chain for specialty chemicals and APIs.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Related-party transaction with promoter group
- Integration risk of the new manufacturing unit
- High dependence on export markets for growth
Key Highlights
Net Profit for Q1 FY27 surged 252% YoY to Rs 5.74 Cr from Rs 1.63 Cr in the previous year
Acquisition of a manufacturing facility from related party Kaygee Laboratories for Rs 29.98 Cr
Export revenue (Outside India) grew 118% YoY to Rs 23.26 Cr in Q1 FY27
Acquisition includes 22,304 sq. mtrs of leasehold land and WHO-Geneva approved API manufacturing facilities
Conversion charges for the quarter stood at Rs 3.32 Cr, which the acquisition aims to internalize
👀 What to Watch
Monitor the completion of the slump sale by the November 30, 2026 deadline and track the subsequent improvement in operating margins as job-work costs are eliminated.
Resonance Specialties Q1 PAT Jumps 252% YoY; to Acquire ₹29.98 Cr Facility
Resonance Specialties reported a robust Q1 FY27 with revenue growing 53.2% YoY to ₹32.58 Cr and Net Profit surging 252% YoY to ₹5.74 Cr. Alongside results, the company announced the acquisition of a manufacturing facility in Mandideep, MP, from a related party for ₹29.98 Cr. This facility, which the company previously used on a job-work basis, is WHO-Geneva approved and will help eliminate outsourcing costs. The acquisition value is significant, representing approximately 33% of the company's TTM revenue and 40% of its net worth.
Confidence: HIGH
What changedThe company is shifting from an asset-light job-work model to owning the manufacturing infrastructure for its key chemical intermediates and APIs.
Why it mattersOwning the WHO-approved facility secures the supply chain, enhances operational control, and is expected to eliminate additional costs associated with outsourcing, potentially boosting long-term margins.
Q1 FY27 Revenue: ₹32.58 CrQ1 FY27 PAT: ₹5.74 CrAcquisition Value: ₹29.98 CrAcquisition vs TTM Revenue: ~33.3%Acquisition vs Net Worth: ~40.5%Export Revenue Growth (YoY): 118.3%
📅 Short termThe stock is likely to react positively to the substantial earnings growth and the strategic move to acquire a key manufacturing asset.
📈 Long termThe acquisition of a WHO-approved facility provides a structural advantage for global API markets and should lead to better margin profiles through vertical integration.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Related-party transaction requires minority shareholder approval
- Integration of the new facility and employees
- Cash outflow of ₹29.98 Cr relative to current cash levels
Key Highlights
Net Profit for Q1 FY27 rose to ₹5.74 Cr from ₹1.63 Cr in the same quarter last year.
Revenue from operations increased to ₹32.58 Cr, driven by a 118% surge in export revenue to ₹23.26 Cr.
Proposed acquisition of a manufacturing unit from Kaygee Laboratories (Related Party) for ₹29.98 Cr on a slump sale basis.
The target facility includes 22,304 sq. mtrs. of leasehold land and is already WHO-Geneva approved.
Earnings per share (EPS) for the quarter stood at ₹4.98, compared to ₹1.41 in Q1 FY26.
👀 What to Watch
Investors should monitor the shareholder approval process for the related-party acquisition and the subsequent impact on operating margins as the company moves from job-work to in-house manufacturing.
Rs 29.98 Cr Acquisition & 53% Revenue Growth in Q1 FY27 for Resonance Specialties
Resonance Specialties reported a strong Q1 FY27 with revenue growing 53% YoY to Rs 32.58 Cr and PAT surging 252% YoY to Rs 5.74 Cr. The board approved the acquisition of a WHO-Geneva approved manufacturing facility in Mandideep from a related party for Rs 29.98 Cr on a slump sale basis. This acquisition represents approximately 40.5% of the company's net worth and aims to internalize production currently handled via job-work. The transaction is expected to close by November 30, 2026, pending shareholder approval.
Confidence: HIGH
What changedThe company is shifting from a job-work model to owning its primary manufacturing facility for key intermediates and APIs, while simultaneously reporting a record quarterly performance.
Why it mattersOwning the WHO-approved facility secures the supply chain, enhances operational control, and eliminates outsourcing costs, which is critical given the company's rapid export growth.
Acquisition Value: Rs 29.98 CrAcquisition vs Net Worth: 40.5%Q1 FY27 EPS: Rs 4.98Export Revenue (Q1): Rs 23.26 CrTarget Completion Date: 30th November 2026
📅 Short termThe stock is likely to react positively to the significant earnings beat and the strategic move to consolidate manufacturing assets.
📈 Long termStructural positive as the company integrates a WHO-certified facility, potentially improving margins and supporting long-term export expansion in the specialty chemicals space.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Related-party transaction with promoter group entity
- Shareholder approval required
- Integration risk of the acquired facility and workforce
Key Highlights
Q1 FY27 Revenue increased 53.2% YoY to Rs 32.58 Cr from Rs 21.27 Cr in Q1 FY26
Net Profit for the quarter jumped to Rs 5.74 Cr, a 252% increase from Rs 1.63 Cr YoY
Acquisition of Mandideep facility for Rs 29.98 Cr, equivalent to ~33% of TTM Revenue
Export revenue grew 118% YoY to Rs 23.26 Cr, now accounting for 71% of total revenue
Acquired facility includes 22,304 sq. mtrs. of leasehold land and is WHO-Geneva approved
👀 What to Watch
Investors should monitor the shareholder voting outcome for this related-party transaction and track the margin profile post-acquisition to see if internalizing production improves OPM beyond the current 15.5%.
Resonance Specialties FY26 PAT Grows 58% to ₹10.40 Cr; Proposes 10% Dividend
Resonance Specialties reported a strong financial performance for FY 2025-26, with total income rising 16.6% YoY to ₹91.89 Cr. Profit After Tax (PAT) saw a significant jump of 58.3%, reaching ₹10.40 Cr compared to ₹6.57 Cr in the previous year. The company has proposed a 10% dividend and demonstrated improved capital efficiency, with Return on Equity (ROE) increasing from 12% to 16%. A key agenda for the upcoming AGM is the approval of related party transactions up to ₹40 Cr.
Confidence: HIGH
What changedThe company has released its audited FY26 annual report, confirming a sharp recovery in profitability and margins compared to the previous two fiscal years.
Why it mattersThe substantial improvement in PAT and ROCE (19%) indicates better operational efficiency and pricing power, while the low debt-equity ratio provides a strong financial cushion for future growth.
Total Income (FY26): ₹9,188.93 LacsProfit After Tax (FY26): ₹1,039.58 LacsProposed Dividend: 10%Return on Equity: 16%RPT Limit vs FY26 Revenue: 43.53%
📅 Short termThe stock may see positive sentiment in the coming weeks driven by the strong earnings growth and the dividend announcement.
📈 Long termThe company is showing a structural improvement in margins and capital efficiency, though the high volume of related party transactions remains a key monitorable.
⚠ Risk flags
- Significant related party transaction limit (₹40 Cr) relative to total revenue
- Inventory turnover ratio slightly declined by 6% YoY
Key Highlights
Total Income increased to ₹9,188.93 Lacs in FY26 from ₹7,878.69 Lacs in FY25
Profit After Tax (PAT) grew by 58.3% YoY to ₹1,039.58 Lacs
Proposed dividend of 10% amounting to a total payout of ₹115.44 Lacs
Debt-Equity ratio improved by 42%, falling to 0.032 from 0.055
Seeking shareholder approval for related party transactions with Kaygee Laboratories up to ₹40 Cr
👀 What to Watch
Investors should monitor the AGM on August 4, 2026, specifically for the approval and terms of the ₹40 Cr related party transaction, which represents a significant portion of annual revenue.
10% Dividend Recommended; 37th AGM Scheduled for August 4, 2026
Resonance Specialties Ltd has announced its 37th Annual General Meeting (AGM) for August 4, 2026. The Board has recommended a dividend of Re. 1 per equity share (10% of face value) for the financial year ended March 31, 2026. The record date for determining dividend eligibility is July 28, 2026, with payment expected by August 28, 2026. Shareholders can participate in remote e-voting between July 31 and August 3, 2026.
Confidence: HIGH
What changedThe company has finalized the schedule for its 37th AGM and established the timeline for its annual dividend distribution.
Why it mattersThis is a routine but essential corporate action that provides liquidity to shareholders and a platform for management to interact with investors regarding the previous year's performance.
Dividend per share: Re. 1/-Dividend percentage: 10%Face Value: Rs. 10/-Record Date: July 28, 2026AGM Date: August 4, 2026
📅 Short termThe stock may trade with a focus on the July 28 record date as investors seek to qualify for the Re. 1 dividend.
📈 Long termLimited; this is a routine annual event and does not signify a structural change in business operations.
Key Highlights
Dividend of Re. 1 per share recommended, representing 10% of the Rs. 10 face value.
Record date for dividend entitlement fixed as July 28, 2026.
37th Annual General Meeting scheduled for August 4, 2026, at 12:30 p.m. via VC/OAVM.
Remote e-voting period set from July 31, 2026 (9:00 a.m.) to August 3, 2026 (5:00 p.m.).
Dividend payment to be completed on or before August 28, 2026, subject to shareholder approval.
👀 What to Watch
Investors should review the FY 2025-26 Annual Report available on the company website for detailed financial performance and management outlook before the AGM.
